

UCLA

UCLA Previously Published Works

Title

Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group

Permalink

<https://escholarship.org/uc/item/5nn4f95q>

Journal

American Journal of Hypertension, 32(12)

ISSN

0895-7061

Authors

Irvin, Marguerite R
Sitlani, Colleen M
Floyd, James S
[et al.](#)

Publication Date

2019-11-15

DOI

10.1093/ajh/hpz150

Peer reviewed

Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group

Marguerite R. Irvin,¹ Colleen M. Sitlani,² James S. Floyd,² Bruce M. Psaty,^{2,3,4,5} Joshua C. Bis,² Kerri L. Wiggins,² Eric A. Whitsel,^{6,7} Til Sturmer,⁷ James Stewart,⁷ Laura Raffield,⁸ Fangui Sun,⁹ Ching-Ti Liu,⁹ Hanfei Xu,⁹ Adrienne L. Cupples,⁹ Rikki M. Tanner,¹ Peter Rossing,¹⁰ Albert Smith,^{11,12} Nuno R. Zilhão,¹¹ Lenore J. Launer,¹³ Raymond Noordam,¹⁴ Jerome I. Rotter,¹⁵ Jie Yao,¹⁵ Xiaohui Li,¹⁵ Xiuqing Guo,¹⁵ Nita Limdi,¹⁶ Aishwarya Sundaresan,¹⁷ Leslie Lange,¹⁸ Adolfo Correa,¹⁹ David J. Stott,²⁰ Ian Ford,²¹ J. Wouter Jukema,²² Vilmundur Gudnason,^{23,24} Dennis O. Mook-Kanamori,¹⁴ Stella Trompet,¹⁴ Walter Palmas,²⁵ Helen R. Warren,^{26,27} Jacklyn N. Hellwege,^{28,29} Ayush Giri,^{28,30} Christopher O'Donnell,^{31,32} Adriana M. Hung,^{28,33} Todd L. Edwards,^{28,34} Tarunveer S. Ahluwalia,^{10,*} Donna K. Arnett,^{35,*} and Christy L. Avery,^{7,*} on behalf of the VA Million Veteran Program and the CHARGE Pharmacogenetics Working Group

BACKGROUND

Only a handful of genetic discovery efforts in apparent treatment-resistant hypertension (aTRH) have been described.

METHODS

We conducted a case-control genome-wide association study of aTRH among persons treated for hypertension, using data from 10

cohorts of European ancestry (EA) and 5 cohorts of African ancestry (AA). Cases were treated with 3 different antihypertensive medication classes and had blood pressure (BP) above goal (systolic BP ≥ 140 mm Hg and/or diastolic BP ≥ 90 mm Hg) or 4 or more medication classes regardless of BP control ($n_{EA} = 931$, $n_{AA} = 228$). Both a normotensive control group and a treatment-responsive control group were considered in separate analyses. Normotensive controls

Correspondence: Marguerite R. Irvin (irvinr@uab.edu).

Initially submitted July 19, 2019; date of first revision September 10, 2019; accepted for publication September 13, 2019; online publication September 23, 2019.

¹Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, USA; ²Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington, USA; ³Department of Epidemiology, University of Washington, Seattle, Washington, USA; ⁴Department of Health Services, University of Washington, Seattle, Washington, USA; ⁵Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA; ⁶Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA; ⁷Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA; ⁸Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA; ⁹Department of Biostatistics, Boston University, Boston, Maryland, USA; ¹⁰Steno Diabetes Center Copenhagen, Gentofte, Denmark; ¹¹Icelandic Heart Association, Kopavogur, Iceland; ¹²University of Iceland, Reykjavik, Iceland; ¹³Laboratory of Epidemiology and Population Science, Intramural Research Program, National Institute on Aging, Bethesda, Maryland, USA; ¹⁴Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands; ¹⁵Institute for Translational Genomics and Population Sciences, Departments of Pediatrics and Medicine, LABioMed at Harbor-UCLA Medical Center, Torrance, California, USA; ¹⁶Department of Neurology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA; ¹⁷Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA; ¹⁸Department of Medicine, University of Colorado-Denver, Aurora, Colorado, USA; ¹⁹Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA; ²⁰Institute of Cardiovascular and Medical Sciences, College of

Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK; ²¹Robertson Center for Biostatistics, University of Glasgow, Glasgow, UK; ²²Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands; ²³Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands; ²⁴Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands; ²⁵Department of Medicine, Columbia University Medical Center, New York, New York, USA; ²⁶William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; ²⁷National Institute for Health Research Barts Cardiovascular Biomedical Research Unit, Queen Mary University of London, London, UK; ²⁸Biomedical Laboratory Research and Development, Tennessee Valley Healthcare System (626)/Vanderbilt University, Nashville, Tennessee, USA; ²⁹Division of Genetic Medicine, Department of Medicine, Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, Tennessee, USA; ³⁰Division of Quantitative Sciences, Department of Obstetrics and Gynecology, Vanderbilt Genetics Institute, Vanderbilt Epidemiology Center, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, Tennessee, USA; ³¹VA Boston Health Care System, Boston, Massachusetts, USA; ³²Section of Cardiology and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; ³³Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA; ³⁴Division of Epidemiology, Department of Medicine, Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, Tennessee, USA; ³⁵Deans Office, School of Public Health, University of Kentucky, Lexington, Kentucky, USA.

*These authors contributed equally.

© American Journal of Hypertension, Ltd 2019. All rights reserved. For Permissions, please email: journals.permissions@oup.com

were untreated ($n_{EA} = 14,210$, $n_{AA} = 2,480$) and had systolic BP/diastolic BP < 140/90 mm Hg. Treatment-responsive controls ($n_{EA} = 5,266$, $n_{AA} = 1,817$) had BP at goal (<140/90 mm Hg), while treated with one antihypertensive medication class. Individual cohorts used logistic regression with adjustment for age, sex, study site, and principal components for ancestry to examine the association of single-nucleotide polymorphisms with case-control status. Inverse variance-weighted fixed-effects meta-analyses were carried out using METAL.

RESULTS

The known hypertension locus, *CASZ1*, was a top finding among EAs ($P = 1.1 \times 10^{-9}$) and in the race-combined analysis ($P = 1.5 \times 10^{-9}$) using the normotensive control group (rs12046278, odds ratio = 0.71 (95%

confidence interval: 0.6–0.8)). Single-nucleotide polymorphisms in this locus were robustly replicated in the Million Veterans Program (MVP) study in consideration of a treatment-responsive control group. There were no statistically significant findings for the discovery analyses including treatment-responsive controls.

CONCLUSION

This genomic discovery effort for aTRH identified *CASZ1* as an aTRH risk locus.

Keywords: blood pressure; hypertension; genome-wide association study; severe hypertension; treatment-resistant hypertension

doi:10.1093/ajh/hpz150

INTRODUCTION

Apparent treatment-resistant hypertension (aTRH) is an extreme form of hypertension (HTN) characterized by the use of 4 or more antihypertensive (AHT) medication classes to achieve blood pressure (BP) control. The estimated prevalence of aTRH in population-based studies is between 12 and 15% among adults with HTN and higher among clinic-based populations, e.g. >25% in those with chronic kidney disease.^{1,2} Risk factors for aTRH are increasing age, obesity, reduced kidney function, and African-American race.¹ Research shows that individuals with aTRH are at an increased risk for cardiovascular disease events when compared with individuals with controlled HTN, demonstrating a need to understand the cause of nonresponse to improve BP control.³ We hypothesized that identifying the genetic architecture may shed light on distinct underlying pathobiology.

Published genetic studies of aTRH have reported limited findings and are lacking in comparison to HTN.^{4–7} The present study comprises European ancestry (EA) and African ancestry (AA) studies from the *Cohorts for Heart and Aging Research in Genomic Epidemiology* (CHARGE) consortium, for a case-control study of aTRH that capitalizes on epidemiological data characterized by deep phenotyping. Common genetic variants in 931 EA aTRH cases were compared with 14,210 normotensive controls and separately to 5,266 treatment-responsive controls, whereas 228 AA aTRH cases were compared with 2,480 normotensive controls and separately to 1,817 treatment-responsive controls. Results were replicated in an aTRH case-control data set from the Million Veterans Program (MVP).

METHODS

Ten studies contributed data on EA participants, whereas 5 studies contributed data on AA participants (Supplementary Section 1). Data on medication use were extracted by medication inventory, self-report, or computerized databases once for cohorts with cross-sectional data, or at each BP measurement for those with longitudinal data (Supplementary Section 1). AHT medications counted toward the sum of classes are described in Supplementary Table 1. Combination products were therapeutically co-classified based on their active ingredients. All diuretics were counted as one class including potassium-sparing diuretics.

Participants with conditions that may lead to secondary forms of HTN (including estimated glomerular filtration rate < 30 ml/min/1.73 m² or body mass index > 40 kg/m²) were excluded. aTRH cases were defined as those treated with 3 AHT medication classes and BP above goal (systolic BP ≥ 140 mm Hg and/or diastolic BP ≥ 90 mm Hg) or 4 or more AHT medication classes regardless of BP control. aTRH cases fitting the above definition who were not treated by a diuretic were excluded.⁸ The analysis included 2 control groups: (i) *Normotensive controls*: participants not hypertensive and not treated with an AHT medication and (ii) *Treatment-responsive controls*: participants who had BP at goal (<140/90 mm Hg) on treatment with one AHT medication class. Details of the case and control definition in cohorts with longitudinal data are described in Supplementary Section 1.

Genome-wide single-nucleotide polymorphism (SNP) genotyping was performed within each study using commercial genotyping arrays (Supplementary Table 2). Cohorts most commonly imputed to the 1000 Genomes version 3 reference panel. After imputation cohorts filtered out SNPs with imputation quality score < 0.3. SNPs with minor allele frequency < 5% and which were not represented in 2 or more cohorts were filtered out at the meta-analysis stage.

Statistical Analysis

Logistic regression models or generalized estimating equations were used for case-control association analysis (Supplementary Table 3). The variable of interest was SNP dosage of the effect allele. Models were adjusted for age, sex, and study-specific covariates (e.g., study site, principal components for ancestry and, if applicable, exchangeable correlation matrices to account for family relatedness). For cohorts with longitudinal data, the average age across the visits included was used as the covariate. In total, there were 4 models, one for each control group and one for each ancestry grouping. Inverse variance-weighted, fixed-effects meta-analysis was performed for each of the 4 strata, using METAL software (www.sph.umich.edu/csg/abecasis/metal/). Statistical heterogeneity across studies was evaluated using Cochran's χ^2 test (Q-test). P -values < 5×10^{-8} indicated genome-wide significant results. Results of the race-stratified analyses from METAL were then combined using

a similar approach (one meta-analysis per control group). Linkage disequilibrium was evaluated using the rAggr tool (<http://raggr.usc.edu/>). Regional plots were created using Locus Zoom with a window of 500 kb (v0.4.8).⁹ In a sensitivity analysis of top SNP results, we conducted a meta-analysis that included only cohorts with >50 cases.

Replication

We sought replication in non-Hispanic EA (78%) and AA (22%) MVP participants (Supplementary Section 1).^{10,11} Participants with estimated glomerular filtration rate \geq 60 ml/min/1.73 m² were included. Total numbers of samples across ethnicities included 16,833 cases (11,762 EAs and 5,071 AAs) and 53,931 controls (42,850 EAs and 11,081 AAs). Cases were defined using the same definition as the discovery analysis. Controls were patients who achieved BP control (<140/90 mm Hg) on 1 or 2 medication classes. Case-control status was regressed onto additively coded genotypes imputed to 1000 Genomes phase 3 version 5, adjusting for age, age², sex, body mass index, and 10 principal components within ethnicity using SNPTEST v2.54. Genotyping, quality control, and imputation procedures have been described.¹⁰

RESULTS

Overall EA and AA cases were older than controls and more likely male (Supplementary Table 4a and 4b). The average number of AHT medication classes for EA cases ranged from 3.2 to 3.8 and from 3.3 to 3.9 for AAs. Across the individual cohort genome-wide association study (GWAS) analyses, there was not excessive evidence for the deviation of *P*-values from their expected values (Supplementary Table 5). Manhattan plots and QQ plots for each discovery meta-analysis are presented in Supplementary Figures 1a–d and 2a–d for the comparison of AA cases to AA normotensive controls, EA cases to EA normotensive controls, AA cases to AA treatment-responsive controls, and EA cases to EA treatment-responsive controls, respectively. Meta-analysis corrected inflation that existed in the cohort-specific analyses.

The top 5 results for each case-control model are presented in Table 1. When comparing aTRH cases to normotensive controls, the top finding for AAs was rs76967376 intronic to myosin-Vb (*MYO5B*). At that SNP, the direction of effect was consistent across each of the 5 cohorts and the odds of being a case were 2.65 (95% confidence interval: 1.9–3.8) times higher among those with the A allele vs. the C allele. Among EAs, the top findings for the normotensive control comparison were intronic to castor zinc finger 1 (*CASZ1*). In the race-combined analysis, *CASZ1* rs12046278 T carriers were less likely to be a case ($P = 1.5 \times 10^{-9}$, odds ratio = 0.71 (95% confidence interval 0.63–0.80)). Another SNP within 3,500 bp to DNA (cytosine-5-)-methyltransferase 3 alpha (*DNMT3A*) was associated with aTRH ($P = 4.9 \times 10^{-8}$) in the race-combined analysis using normotensive controls. Regional plots (Supplementary Figures 3–5) for rs76967376 (*MYO5B*), rs12046278 (*CASZ1*), and rs11674660 (near

DNMT3A) display linkage disequilibrium support for these top findings. Results of the race-combined analysis are presented in Supplementary Table 6 and Supplementary Figure 6.

When comparing aTRH cases to treatment-responsive controls no SNP was statistically significant after correcting for multiple testing in either racial stratum. Race-combined analysis did not increase the significance of top hits. In the sensitivity analysis limiting contributing cohorts to those with >50 cases results were generally consistent with the main findings in Table 1 (Supplementary Table 7).

The MVP cases in the replication study were older (63 ± 9 vs. 62 ± 10 years for EAs and 58 ± 9 vs. 56 ± 10 years for AAs) and had slightly higher body mass index compared with the treatment-responsive controls. Results for AAs as well as the EAs for the treatment-responsive control group were not replicated in the MVP. However, results from the EA discovery for the normotensive control group were robustly replicated with the same direction of effect for SNPs in *CASZ1* ($P < 5 \times 10^{-8}$) and the direction of association for rs11674660 intergenic to *DNMT3A*, *DTNB* was consistent in direction but not statistically significant ($P = 0.09$) (Supplementary Table 8).

DISCUSSION

Although the genetics of BP and essential HTN have been extensively investigated, few genetic studies have explored genes associated with less common and more severe aTRH. Using data available from observational epidemiological cohort studies, the current meta-GWAS study examined SNPs associated with aTRH in EA and AA cases with respect to 2 different control sets. Our study confirmed the known BP locus, *CASZ1*, as being robustly associated with aTRH in the discovery and replication data set. Other notable findings, *MYO5B* and *DMNT3A/DTNB*, warrant additional replication efforts.

To our knowledge our top finding in the AA stratum (rs76967376 in *MYO5B* involved in cell trafficking and plasma membrane recycling) has been associated with lipid levels in previous GWAS, but has not been associated with HTN. The nearest published BP locus (rs745821) is in the *MAK4* gene (~505 kb in distance) and is not in linkage disequilibrium with our finding ($r^2 < 0.01$).¹² At least one animal model has reported *MYO5B* may regulate an atrial voltage-gated potassium channel (Kv1.5) important for cardiac excitability.¹³ This result was not replicated in the MVP aTRH case-control data set. Future studies may still be warranted given the differences in the replication data set that used treatment-responsive controls with estimated glomerular filtration rate \geq 60 ml/min/1.73 m². The top finding among EAs was the known HTN locus *CASZ1*, a zinc finger transcription factor which plays a key role in cardiac development and postnatal adaptation.¹⁴ The gene has been previously associated with BP and HTN in Asian ancestry and EA populations.^{15–17} The biological role of *CASZ1* in aTRH needs additional investigation but may be related to expression changes in genes that regulate BP or AHT response.¹⁸ Taken together the significant results from the discovery and

Table 1. Top hits for genome-wide case-control association analysis of apparent treatment-resistant hypertension

| rs# | CHR | A1/A2 | EAF | OR | 95% CI | P-value | Direction* | Location | Gene(s) |
|----------------------|-----|-------|------|-------|-------------|----------|--------------|------------|-----------------|
| 228 AA cases | | | | | | | | | |
| 2,490 normotensive* | | | | | | | | | |
| rs76967376 | 18 | A/C | 0.11 | 2.65 | 1.87, 3.78 | 5.75E-08 | +++++ | Intronic | MYO5B |
| rs185169399 | 5 | A/G | 0.94 | 11.96 | 4.53, 31.55 | 5.27E-07 | +++?+ | Intergenic | CDH18 |
| rs114349263 | 5 | A/C | 0.06 | 0.08 | 0.03, 0.22 | 5.52E-07 | ---?- | Intergenic | CDH18 |
| rs12665245 | 6 | T/C | 0.86 | 0.36 | 0.24, 0.54 | 1.34E-06 | ----? | Intronic | ENPP3 |
| rs143255889 | 10 | C/G | 0.07 | 3.10 | 1.95, 4.92 | 1.80E-06 | +++++ | Intergenic | LINC01519 |
| 1,817 hypertensive* | | | | | | | | | |
| rs138399316 | 6 | T/C | 0.15 | 5.85 | 3.00, 11.37 | 1.89E-07 | ++?+? | Intronic | BPHL |
| rs146183009 | 1 | A/G | 0.11 | 2.49 | 1.75, 3.54 | 4.41E-07 | +++++ | Intronic | ICMT |
| rs111285947 | 17 | A/G | 0.06 | 3.89 | 2.21, 6.83 | 2.16E-06 | +?+++? | Downstream | LINC00670 |
| rs1651805 | 19 | C/G | 0.26 | 1.84 | 1.43, 2.36 | 2.17E-06 | +++++ | Intergenic | LSM14A,KIAA0355 |
| rs114511751 | 1 | T/C | 0.10 | 2.44 | 1.68, 3.53 | 2.20E-06 | +++++ | Intronic | TMCC2 |
| 931 EA cases | | | | | | | | | |
| 14,201 normotensive* | | | | | | | | | |
| rs12046278 | 1 | T/C | 0.63 | 0.71 | 0.63, 0.80 | 1.11E-08 | -----? | Intronic | CASZ1 |
| rs34071855 | 1 | C/G | 0.64 | 0.72 | 0.64, 0.81 | 4.87E-08 | -----+ | Intronic | CASZ1 |
| rs11674660 | 2 | T/C | 0.15 | 1.53 | 1.31, 1.80 | 7.63E-08 | +++-+++-++++ | Intergenic | DNMT3A,DTNB |
| rs17035646 | 1 | A/G | 0.35 | 1.36 | 1.26, 1.59 | 7.90E-08 | +++++----- | Intronic | CASZ1 |
| rs880315 | 1 | T/C | 0.65 | 0.74 | 0.66, 0.83 | 1.19E-07 | -----+ | Intronic | CASZ1 |
| 5,266 hypertensive* | | | | | | | | | |
| rs74725390 | 7 | T/C | 0.07 | 1.70 | 1.38, 2.09 | 5.36E-07 | +++--++++-? | Intergenic | COBL,POM121L12 |
| rs12050053 | 13 | T/G | 0.06 | 2.43 | 1.71, 3.47 | 8.39E-07 | +++??+??+??? | Intergenic | EEF1DP3,FRY-AS1 |
| rs4844662 | 1 | C/G | 0.47 | 1.31 | 1.18, 1.47 | 9.01E-07 | +++----- | Intronic | PLXNA2 |
| rs111281682 | 7 | A/G | 0.83 | 0.72 | 0.63, 0.82 | 1.63E-06 | +----+----- | Intergenic | MYL10,CUX1 |
| rs77270397 | 13 | A/G | 0.07 | 2.09 | 1.54, 2.82 | 1.75E-06 | +++??+--+++? | Intergenic | EEF1DP3,FRY-AS1 |

AA order: ARIC, HyperGEN, JHS, PHG, MESA. EA order: normotensive, AFTER-EU, AGES, ARIC, HyperGEN, NEO, CHS, HVH1 cases, HVH1 controls, HVH2 cases, HVH2 controls, PROSPER, FHS, MESA. EA order: treatment responsive, AFTER-EU, AGES, ARIC, HyperGEN, NEO, CHS, HVH1 cases, HVH1 controls, HVH2 cases, HVH2 controls, PROSPER, MESA. Significant P-value after correction for multiple testing 5×10^{-8}. Abbreviations: AA, African American, EA, European American, EAF, effect allele frequency; OR, odds ratio; CI, confidence interval; A1, allele 1, effect allele; A2, allele 2.

*Controls.

replication analysis suggest *CASZ1* is an aTRH locus among EAs. The result for the top SNP was consistent but marginally significant for AAs in CHARGE (odds ratio = 0.69 (95% confidence interval: 0.48–0.99); $P = 0.04$ for the T allele). Rs880315 in *CASZ1* from Table 1 was marginally significant in MVP AAs (odds ratio = 1.09 (95% confidence interval: 1.03–1.15); $P = 0.008$ for the C allele). Loci near *DMNT3A/DTNB* on chromosome 2 have been identified in a recent BP GWAS study (~300 kb downstream of *ADCY3*) though rs11674660 from our study and previously published *ADCY3* rs55701159 are not in linkage disequilibrium ($r^2 < 0.01$).¹² *DMNT3A* is causal for clonal hematopoiesis of indeterminate potential (CHIP), and mutations in *DMNT3A* have been associated with coronary heart disease.¹⁹ The isoprenylcysteine carboxyl methyltransferase (*ICMT*) locus was the only gene near a previously identified HTN gene

(~15 kb downstream of *RNF207* rs709209)²⁰ that we report on for the treatment-responsive control group. The SNP rs11674660 near *DMNT3A/DTNB* and rs146183009 in *ICMT* were not replicated in the MVP.

We also compared our results with published GWAS studies.^{5,6} In the electronic MEDical Records & Genomics study among 3,006 cases and 876 treatment-responsive controls, there were no statistically significant findings. In the International Verapamil SR Trandolapril Study GENetic Substudy, an SNP (rs12817819) in ATPase Plasma Membrane Ca²⁺ Transporting 1 (*ATP2B1*) was associated with aTRH in EAs and Hispanics. In our data, SNPs in *ATP2B1* were most strongly associated with aTRH when cases were compared with normotensive controls (AAs rs58302337 ($P = 0.001$), rs12580678 ($P = 0.004$); EAs rs1401982 ($P = 0.006$)) vs. treatment responsive controls (AAs rs152754 ($P = 0.01$); EAs

rs34205054 ($P = 0.006$)). Differences between these studies and our own include the use of clinical rather than observational populations and the consideration of only controlled hypertensive patients as controls.

Strengths of the present study include collaboration among well-characterized cardiovascular disease cohorts for which BP measurement and the recording of AHT information was a focus. Furthermore, we replicated our findings in a large data set with comparable ethnic groups. However, aTRH is complex and our study had several weaknesses including lack of information on white coat HTN, adherence information, and medication dosage data, which may contribute to phenotypic misclassification which could dilute our results. We were unable to distinguish AHT use for conditions other than HTN such as glaucoma. Other limitations included heterogeneity among study populations regarding phenotypic focus (e.g., obesity, cardiovascular disease) and different methods for the measurement of BP. Finally, the case-control group available for the replication analysis was not identical to our discovery data set.

Despite being common among persons with HTN, little is known about the genetic etiology of aTRH. In this discovery and replication effort, the main finding included a transcription factor and known HTN locus involved in cardiac development (*CASZ1*). *MYO5B* and *DMNT3A/DTNB* were biologically interesting cardiovascular candidates that were not replicated but remain worthy of further investigation for this severe form of HTN.

SUPPLEMENTARY MATERIAL

Supplementary data are available at *American Journal of Hypertension* online.

ACKNOWLEDGMENTS

Million Veterans Program (MVP): Consortium Acknowledgment for Manuscripts

MVP Executive Committee

- Co-chair: J. Michael Gaziano, MD, MPH
- Co-chair: Rachel Ramoni, DMD, ScD
- Jean Beckham, PhD
- Jim Breeling, MD (ex-officio)
- Kyong-Mi Chang, MD
- Grant Huang, PhD (ex-officio)
- Sumitra Muralidhar, PhD
- Christopher J. O'Donnell, MD, MPH
- Philip S. Tsao, PhD

MVP Program Office

- Sumitra Muralidhar, PhD
- Jennifer Moser, PhD

MVP Recruitment/Enrollment

- Recruitment/Enrollment Director/Deputy Director, Boston—Stacey B. Whitbourne, PhD; Jessica V. Brewer, MPH

- MVP Coordinating Centers
 - Clinical Epidemiology Research Center (CERC), West Haven—John Concato, MD, MPH
 - Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque—Stuart Warren, JD, Pharm D; Dean P. Argyres, MS
 - Genomics Coordinating Center, Palo Alto—Philip S. Tsao, PhD
 - Massachusetts Veterans Epidemiology Research Information Center (MAVERIC), Boston—J. Michael Gaziano, MD, MPH
 - MVP Information Center, Canandaigua—Brady Stephens, MS
- Core Biorepository, Boston—Mary T. Brophy, MD, MPH; Donald E. Humphries, PhD
- MVP Informatics, Boston—Nhan Do, MD; Shahpoor Shayan
- Data Operations/Analytics, Boston—Xuan-Mai T. Nguyen, PhD

MVP Science

- Genomics—Christopher J. O'Donnell, MD, MPH; Saiju Pyarajan, PhD; Philip S. Tsao, PhD
- Phenomics—Kelly Cho, MPH, PhD
- Data and Computational Sciences—Saiju Pyarajan, PhD
- Statistical Genetics—Elizabeth Hauser, PhD; Yan Sun, PhD; Hongyu Zhao, PhD

MVP Local Site Investigators

- Atlanta VA Medical Center (Peter Wilson)
- Bay Pines VA Healthcare System (Rachel McArdle)
- Birmingham VA Medical Center (Louis Dellitalia)
- Cincinnati VA Medical Center (John Harley)
- Clement J. Zablocki VA Medical Center (Jeffrey Whittle)
- Durham VA Medical Center (Jean Beckham)
- Edith Nourse Rogers Memorial Veterans Hospital (John Wells)
- Edward Hines, Jr. VA Medical Center (Salvador Gutierrez)
- Fayetteville VA Medical Center (Gretchen Gibson)
- VA Health Care Upstate New York (Laurence Kaminsky)
- New Mexico VA Health Care System (Gerardo Villareal)
- VA Boston Healthcare System (Scott Kinlay)
- VA Western New York Healthcare System (Junzhe Xu)
- Ralph H. Johnson VA Medical Center (Mark Hamner)
- Wm. Jennings Bryan Dorn VA Medical Center (Kathlyn Sue Haddock)
- VA North Texas Health Care System (Sujata Bhushan)
- Hampton VA Medical Center (Pran Iruvanti)
- Hunter Holmes McGuire VA Medical Center (Michael Godschalk)
- Iowa City VA Health Care System (Zuhair Ballas)
- Jack C. Montgomery VA Medical Center (Malcolm Buford)
- James A. Haley Veterans' Hospital (Stephen Mastorides)
- Louisville VA Medical Center (Jon Klein)
- Manchester VA Medical Center (Nora Ratcliffe)
- Miami VA Health Care System (Hermes Florez)
- Michael E. DeBakey VA Medical Center (Alan Swann)
- Minneapolis VA Health Care System (Maureen Murdoch)

- N. FL/S. GA Veterans Health System (Peruvemba Sriram)
- Northport VA Medical Center (Shing Shing Yeh)
- Overton Brooks VA Medical Center (Ronald Washburn)
- Philadelphia VA Medical Center (Darshana Jhala)
- Phoenix VA Health Care System (Samuel Aguayo)
- Portland VA Medical Center (David Cohen)
- Providence VA Medical Center (Satish Sharma)
- Richard Roudebush VA Medical Center (John Callaghan)
- Salem VA Medical Center (Kris Ann Oursler)
- San Francisco VA Health Care System (Mary Whooley)
- South Texas Veterans Health Care System (Sunil Ahuja)
- Southeast Louisiana Veterans Health Care System (Amparo Gutierrez)
- Southern Arizona VA Health Care System (Ronald Schifman)
- Sioux Falls VA Health Care System (Jennifer Greco)
- St. Louis VA Health Care System (Michael Rauchman)
- Syracuse VA Medical Center (Richard Servatius)
- VA Eastern Kansas Health Care System (Mary Oehlert)
- VA Greater Los Angeles Health Care System (Agnes Wallbom)
- VA Loma Linda Healthcare System (Ronald Fernando)
- VA Long Beach Healthcare System (Timothy Morgan)
- VA Maine Healthcare System (Todd Stapley)
- VA New York Harbor Healthcare System (Scott Sherman)
- VA Pacific Islands Health Care System (Gwenevere Anderson)
- VA Palo Alto Health Care System (Philip Tsao)
- VA Pittsburgh Health Care System (Elif Sonel)
- VA Puget Sound Health Care System (Edward Boyko)
- VA Salt Lake City Health Care System (Laurence Meyer)
- VA San Diego Healthcare System (Samir Gupta)
- VA Southern Nevada Healthcare System (Joseph Fayad)
- VA Tennessee Valley Healthcare System (Adriana Hung)
- Washington DC VA Medical Center (Jack Lichy)
- W.G. (Bill) Hefner VA Medical Center (Robin Hurley)
- White River Junction VA Medical Center (Brooks Robey)
- William S. Middleton Memorial Veterans Hospital (Robert Striker)

FUNDING

Age, Gene, Environment, Susceptibility—Reykjavik Study (AGES) has been funded by NIH contracts N01-AG-1-2100 and HHSN271201200022C, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament). The study is approved by the Icelandic National Bioethics Committee (VSN: 00-476 063). The researchers are indebted to the participants for their willingness to participate in the study.

The **Atherosclerosis Risk in Communities (ARIC)** study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services (contract numbers HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I, and HHSN268201700005I), R01HL087641, R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. The

authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by grant number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research.

The **Cardiovascular Health Study (CHS)** was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, HHSN268200960009C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, and N01HC85086, and NHLBI Grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, R01HL120393, U01HL130114, and R01HL085251 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI Grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) Grant DK063491 to the Southern California Diabetes Endocrinology Research Center. J.S.F. was supported by K08HL116640.

The **Heart and Vascular Health Study** has been funded in part by NHLBI grants R01HL085251 and R01HL073410.

The **HyperGEN: Genetics of Left Ventricular Hypertrophy** is ancillary to the Family Blood Pressure Program, <http://clinicaltrials.gov/ct/show/NCT00005267>. Funding sources included National Heart, Lung, and Blood Institute grant R01HL055673 and cooperative agreements (U01) with the National Heart, Lung, and Blood Institute: U01HL054471, U01HL54515 (UT); U01HL054472, 471 U01HL054496 (MN); U01HL054473 (DCC); U01HL054495 (AL); U01HL054509 (NC).

The authors of the **Netherlands Epidemiology of Obesity (NEO)** study thank all individuals who participated in the Netherlands Epidemiology in Obesity study, all participating general practitioners for inviting eligible participants and all research nurses for collection of the data. We thank the NEO study group, Pat van Beelen, Petra Noordijk, and Ingeborg de Jonge for the coordination, lab, and data management of the NEO study. The genotyping in the NEO study was supported by the Centre National de Génotypage (Paris, France), headed by Jean-Francois Deleuze. The NEO study is supported by the participating Departments, the Division, and the Board of Directors of the Leiden University Medical Center and by the Leiden University, Research Profile Area Vascular and Regenerative Medicine. D.O.M.-K. is supported by Dutch Science Organization (ZonMW-VENI Grant 916.14.023).

The **Jackson Heart Study (JHS)** is supported and conducted in collaboration with Jackson State University (HHSN268201800013I), Tougaloo College (HHSN268201800014I), the Mississippi State Department of Health (HHSN268201800015I), and the University of Mississippi Medical Center (HHSN268201800010I, HHSN268201800011I, and HHSN268201800012I) contracts from the National Heart, Lung, and Blood Institute (NHLBI)

and the National Institute for Minority Health and Health Disparities (NIMHD). The authors also wish to thank the staffs and participants of the JHS. L.M.R. is funded by T32 HL12998. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services.

Multi-ethnic Study of Atherosclerosis (MESA) and the MESA SHARe project are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420. Funding for SHARe genotyping was provided by NHLBI contract N02-HL-64278. Genotyping was performed at Affymetrix (Santa Clara, CA) and the Broad Institute of Harvard and MIT (Boston, MA) using the Affymetrix Genome-Wide Human SNP Array 6.0. Also supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center.

The **Prospective study of Pravastatin in the Elderly at Risk (PROSPER)** study was supported by an investigator-initiated grant obtained from Bristol-Myers Squibb. Prof. Dr. J. W. Jukema is an Established Clinical Investigator of the Netherlands Heart Foundation (grant 2001 D 032). Support for genotyping was provided by the seventh framework program of the European Commission (grant 223004) and by the Netherlands Genomics Initiative (Netherlands Consortium for Healthy Aging grant 050-060-810).

The **AfterEU** study is the Danish part of the EURAGEDIC study, which was supported by the European Commission (contract QLG2-CT-2001-01669). The genotyping for this study was part of the Genetics of Diabetic Nephropathy (Gen DN) study, primarily funded by Juvenile Diabetes Research Foundation (JDRF) International Prime Award Number 17-2013-8. T.S.A. was also funded by the GenDN grant and acknowledges the same. Additionally, TSA was supported by internal funding from Steno Diabetes Center Copenhagen, Gentofte, Denmark and from the Novo Nordisk Foundation (Steno Collaborative 2018) Grant NNF18OC0052457 and acknowledged the same. No potential conflicts of interest relevant to this article were reported. The authors acknowledge the technical assistance of Tina R. Juhl, Anne G. Lundgaard, Berit R. Jensen, and Ulla M. Smidt. In addition, the authors thank Dr. Steve Rich, who was involved in genotyping from the University of Virginia, USA.

This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration and was supported by award I01BX003360 to A.M.H. This work was supported using resources and facilities of the VA Informatics and Computing Infrastructure (VINCI), VA HSR RES 13-457. J.N.H. and

A.G. are supported by the Building Interdisciplinary Research Careers in Women's Health Career Development Program grant K12HD043483 (PI: K.E. Hartmann). T.L.E. was supported by NIH/NHLBI grant HL121429.

DISCLOSURE

The authors declared no conflict of interest.

REFERENCES

- Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. *Circulation* 2011; 124:1046–1058.
- Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, Lackland DT, Laffer CL, Newton-Cheh C, Smith SM, Taler SJ, Textor SC, Turan TN, White WB; American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council. Resistant hypertension: detection, evaluation, and management: a Scientific Statement From the American Heart Association. *Hypertension* 2018; 72:e53–e90.
- Irvin MR, Booth JN 3rd, Shimbo D, Lackland DT, Oparil S, Howard G, Safford MM, Muntner P, Calhoun DA. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. *J Am Soc Hypertens* 2014; 8:405–413.
- Lynch AI, Irvin MR, Davis BR, Ford CE, Eckfeldt JH, Arnett DK. Genetic and adverse health outcome associations with treatment resistant hypertension in GenHAT. *Int J Hypertens* 2013; 2013:578578.
- Dumitrescu L, Ritchie MD, Denny JC, El Rouby NM, McDonough CW, Bradford Y, Ramirez AH, Bielski SJ, Basford MA, Chai HS, Peissig P, Carrell D, Pathak J, Rasmussen LV, Wang X, Pacheco JA, Kho AN, Hayes MG, Matsumoto M, Smith ME, Li R, Cooper-DeHoff RM, Kullo JJ, Chute CG, Chisholm RL, Jarvik GP, Larson EB, Carey D, McCarty CA, Williams MS, Roden DM, Bottinger E, Johnson JA, de Andrade M, Crawford DC. Genome-wide study of resistant hypertension identified from electronic health records. *PLoS One* 2017; 12:e0171745.
- Fontana V, McDonough CW, Gong Y, El Rouby NM, Sá AC, Taylor KD, Chen YD, Gums JG, Chapman AB, Turner ST, Pepine CJ, Johnson JA, Cooper-DeHoff RM. Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension. *J Am Heart Assoc* 2014; 3:e001398.
- El Rouby N, McDonough CW, Gong Y, McClure LA, Mitchell BD, Horenstein RB, Talbert RL, Crawford DC, Gitzendanner MA, Takahashi A, Tanaka T, Kubo M, Pepine CJ, Cooper-DeHoff RM, Benavente OR, Shuldiner AR, Johnson JA; eMERGE Network. Genome-wide association analysis of common genetic variants of resistant hypertension. *Pharmacogenomics J* 2019; 19:295–304.
- Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. *Circulation* 2008; 117:e510–e526.
- Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Glied TP, Boehnke M, Abecasis GR, Willer CJ. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics* 2010; 26:2336–2337.
- Giri A, Hellwege JN, Keaton JM, Park J, Qiu C, Warren HR, Torstenson ES, Kovesdy CP, Sun YV, Wilson OD, Robinson-Cohen C, Roumie CL, Chung CP, Birdwell KA, Damrauer SM, DuVall SL, Klarin D, Cho K, Wang Y, Evangelou E, Cabrera CP, Wain LV, Shrestha R, Mautz BS,

- Akwo EA, Sargurupremraj M, Debette S, Boehnke M, Scott LJ, Luan J, Zhao JH, Willems SM, Thériault S, Shah N, Oldmeadow C, Almgren P, Li-Gao R, Verweij N, Boutin TS, Mangino M, Ntalla I, Feofanova E, Surendran P, Cook JP, Karthikeyan S, Lahrouchi N, Liu C, Sepúlveda N, Richardson TG, Kraja A, Amouyel P, Farrall M, Poulter NR, Laakso M, Zeggini E, Sever P, Scott RA, Langenberg C, Wareham NJ, Conen D, Palmer CNA, Attia J, Chasman DI, Ridker PM, Melander O, Mook-Kanamori DO, Harst PV, Cucca F, Schlessinger D, Hayward C, Spector TD, Jarvelin MR, Hennig BJ, Timpson NJ, Wei WQ, Smith JC, Xu Y, Matheny ME, Siew EE, Lindgren C, Herzig KH, Dedoussis G, Denny JC, Psaty BM, Howson JMM, Munroe PB, Newton-Cheh C, Caulfield MJ, Elliott P, Gaziano JM, Concato J, Wilson PWF, Tsao PS, Velez Edwards DR, Susztak K, O'Donnell CJ, Hung AM, Edwards TL; Understanding Society Scientific Group; International Consortium for Blood Pressure; Blood Pressure-International Consortium of Exome Chip Studies; Million Veteran Program. Trans-ethnic association study of blood pressure determinants in over 750,000 individuals. *Nat Genet* 2019; 51:51–62.
11. Gaziano JM, Concato J, Brophy M, Fiore L, Pyarajan S, Breeling J, Whitbourne S, Deen J, Shannon C, Humphries D, Guarino P, Aslan M, Anderson D, LaFleur R, Hammond T, Schaa K, Moser J, Huang G, Muralidhar S, Przygodzki R, O'Leary TJ. Million veteran program: a mega-biobank to study genetic influences on health and disease. *J Clin Epidemiol* 2016; 70:214–223.
 12. Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, Ntalla I, Surendran P, Liu C, Cook JP, Kraja AT, Drenos F, Loh M, Verweij N, Marten J, Karaman I, Lepe MP, O'Reilly PF, Knight J, Snieder H, Kato N, He J, Tai ES, Said MA, Porteous D, Alver M, Poulter N, Farrall M, Gansevoort RT, Padmanabhan S, Mägi R, Stanton A, Connell J, Bakker SJ, Metspalu A, Shields DC, Thom S, Brown M, Sever P, Esko T, Hayward C, van der Harst P, Saleheen D, Chowdhury R, Chambers JC, Chasman DI, Chakravarti A, Newton-Cheh C, Lindgren CM, Levy D, Kooner JS, Keavney B, Tomaszewski M, Samani NJ, Howson JM, Tobin MD, Munroe PB, Ehret GB, Wain LV; International Consortium of Blood Pressure (ICBP) 1000G Analyses; BIOS Consortium; Lifelines Cohort Study; Understanding Society Scientific group; CHD Exome+ Consortium; ExomeBP Consortium; T2D-GENES Consortium; GoT2DGenes Consortium; Cohorts for Heart and Ageing Research in Genome Epidemiology (CHARGE) BP Exome Consortium; International Genomics of Blood Pressure (iGEN-BP) Consortium; UK Biobank CardioMetabolic Consortium BP working group. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. *Nat Genet* 2017; 49:403–415.
 13. Schumacher-Bass SM, Vesely ED, Zhang L, Ryland KE, McEwen DP, Chan PJ, Frasier CR, McIntyre JC, Shaw RM, Martens JR. Role for myosin-V motor proteins in the selective delivery of Kv channel isoforms to the membrane surface of cardiac myocytes. *Circ Res* 2014; 114:982–992.
 14. Huang RT, Xue S, Wang J, Gu JY, Xu JH, Li YJ, Li N, Yang XX, Liu H, Zhang XD, Qu XK, Xu YJ, Qiu XB, Li RG, Yang YQ. CASZ1 loss-of-function mutation associated with congenital heart disease. *Gene* 2016; 595:62–68.
 15. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, Glazer NL, Morrison AC, Johnson AD, Aspelund T, Aulchenko Y, Lumley T, Köttgen A, Vasan RS, Rivadeneira F, Eiriksdottir G, Guo X, Arking DE, Mitchell GF, Mattace-Raso FU, Smith AV, Taylor K, Scharpf RB, Hwang SJ, Sijbrands EJ, Bis J, Harris TB, Ganesh SK, O'Donnell CJ, Hofman A, Rotter JJ, Coresh J, Benjamin EJ, Uitterlinden AG, Heiss G, Fox CS, Witteman JC, Boerwinkle E, Wang TJ, Gudnason V, Larson MG, Chakravarti A, Psaty BM, van Duijn CM. Genome-wide association study of blood pressure and hypertension. *Nat Genet* 2009; 41:677–687.
 16. Lu X, Wang L, Lin X, Huang J, Charles Gu C, He M, Shen H, He J, Zhu J, Li H, Hixson JE, Wu T, Dai J, Lu L, Shen C, Chen S, He L, Mo Z, Hao Y, Mo X, Yang X, Li J, Cao J, Chen J, Fan Z, Li Y, Zhao L, Li H, Lu F, Yao C, Yu L, Xu L, Mu J, Wu X, Deng Y, Hu D, Zhang W, Ji X, Guo D, Guo Z, Zhou Z, Yang Z, Wang R, Yang J, Zhou X, Yan W, Sun N, Gao P, Gu D. Genome-wide association study in Chinese identifies novel loci for blood pressure and hypertension. *Hum Mol Genet* 2015; 24:865–874.
 17. Takeuchi F, Isono M, Katsuya T, Yamamoto K, Yokota M, Sugiyama T, Nabika T, Fujioka A, Ohnaka K, Asano H, Yamori Y, Yamaguchi S, Kobayashi S, Takayanagi R, Ogihara T, Kato N. Blood pressure and hypertension are associated with 7 loci in the Japanese population. *Circulation* 2010; 121:2302–2309.
 18. Liu Z, Yang X, Li Z, McMahon C, Sizer C, Barenboim-Stapleton L, Bliskovsky V, Mock B, Ried T, London WB, Maris J, Khan J, Thiele CJ. CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression. *Cell Death Differ* 2011; 18:1174–1183.
 19. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, Baber U, Mehran R, Fuster V, Danesh J, Frossard P, Saleheen D, Melander O, Sukhova GK, Neuberg D, Libby P, Kathiresan S, Ebert BL. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. *N Engl J Med* 2017; 377:111–121.
 20. Surendran P, Drenos F, Young R, Warren H, Cook JP, Manning AK, Grarup N, Sim X, Barnes DR, Witkowska K, Staley JR, Tragante V, Tukiainen T, Yaghootkar H, Masca N, Freitag DF, Ferreira T, Giannakopoulou O, Tinker A, Harakalova M, Mihailov E, Liu C, Kraja AT, Fallgaard Nielsen S, Rasheed A, Samuel M, Zhao W, Bonnycastle LL, Jackson AU, Narisu N, Swift AJ, Southam L, Marten J, Huyghe JR, Stančáková A, Fava C, Ohlsson T, Matchan A, Stirrups KE, Bork-Jensen J, Gjesing AP, Kontto J, Perola M, Shaw-Hawkins S, Havulinna AS, Zhang H, Donnelly LA, Groves CJ, Rayner NW, Neville MJ, Robertson NR, Yorlankas AM, Herzig KH, Kajantie E, Zhang W, Willems SM, Lannfelt L, Malerba G, Soranzo N, Trabetti E, Verweij N, Evangelou E, Moayyeri A, Vergnaud AC, Nelson CP, Poveda A, Varga TV, Caslake M, de Craen AJ, Trompet S, Luan J, Scott RA, Harris SE, Liewald DC, Marioni R, Menni C, Farmaki AE, Hallmans G, Renström F, Huffman JE, Hassinen M, Burgess S, Vasan RS, Felix JF, Uria-Nickelsen M, Malarstig A, Reilly DF, Hoek M, Vogt T, Lin H, Lieb W, Traylor M, Markus HF, Highland HM, Justice AE, Marouli E, Lindström J, Uusitupa M, Komulainen P, Lakka TA, Rauramaa R, Polasek O, Rudan I, Rolandsson O, Franks PW, Dedoussis G, Spector TD, Jousilahti P, Männistö S, Deary IJ, Starr JM, Langenberg C, Wareham NJ, Brown MJ, Dominiczak AF, Connell JM, Jukema JW, Sattar N, Ford I, Packard CJ, Esko T, Mägi R, Metspalu A, de Boer RA, van der Meer P, van der Harst P, Gambaro G, Ingelsson E, Lind L, de Bakker PI, Numans ME, Brandlund I, Christensen C, Petersen ER, Korpi-Hyövälti E, Oksa H, Chambers JC, Kooner JS, Blakemore AI, Franks S, Jarvelin MR, Husemoen LL, Linneberg A, Skaaby T, Thuesen B, Karpe F, Tuomilehto J, Doney AS, Morris AD, Palmer CN, Holmen OL, Hveem K, Willer CJ, Tuomi T, Groop L, Käräjämäki A, Palotie A, Ripatti S, Salomaa V, Alam DS, Shafi Majumder AA, Di Angelantonio E, Chowdhury R, McCarthy MI, Poulter N, Stanton AV, Sever P, Amouyel P, Arveiler D, Blankenberg S, Ferrières J, Kee F, Kuulasmaa K, Müller-Nurasyid M, Veronesi G, Virtamo J, Deloukas P, Elliott P, Zeggini E, Kathiresan S, Melander O, Kuusisto J, Laakso M, Padmanabhan S, Porteous D, Hayward C, Scotland G, Collins FS, Mohlke KL, Hansen T, Pedersen O, Boehnke M, Stringham HM, Frossard P, Newton-Cheh C, Tobin MD, Nordestgaard BG, Caulfield MJ, Mahajan A, Morris AP, Tomaszewski M, Samani NJ, Saleheen D, Asselbergs FW, Lindgren CM, Danesh J, Wain LV, Butterworth AS, Howson JM, Munroe PB; CHARGE-Heart Failure Consortium; EchoGen Consortium; METASTROKE Consortium; GIANT Consortium; EPIC-InterAct Consortium; Lifelines Cohort Study; Wellcome Trust Case Control Consortium; Understanding Society Scientific Group; EPIC-CVD Consortium; CHARGE+ Exome Chip Blood Pressure Consortium; T2D-GENES Consortium; GoT2DGenes Consortium; ExomeBP Consortium; CHD Exome+ Consortium. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. *Nat Genet* 2016; 48:1151–1161.